Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Fang, Ying  [Clear All Filters]
2024
Shi J, Yu X, Li G, Zhao X, Chen J, Fang Y, Yang Y, Wang T, Xu T, Bian L, et al. DTL promotes head and neck squamous cell carcinoma progression by mediating the degradation of ARGLU1 to regulate the Notch signaling pathway. Int J Biol Macromol. 2024:129184.
Fang Y, Ye P-P. [Research Progress on the Application Strategies of Plerixafor in the Peripheral Blood Stem Cell Mobilization for Autologous Transplantation--Review]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2024;32(1):322-326.
2023
Li Y-R, Lyu Z, Tian Y, Fang Y, Zhu Y, Chen Y, Yang L. Advancements in CRISPR screens for the development of cancer immunotherapy strategies. Mol Ther Oncolytics. 2023;31:100733.
Li Y-R, Fang Y, Lyu Z, Zhu Y, Yang L. Exploring the dynamic interplay between cancer stem cells and the tumor microenvironment: implications for novel therapeutic strategies. J Transl Med. 2023;21(1):686.
Fang Y, Zhang M-C, He Y, Li C, Fang H, Xu P-P, Cheng S, Zhao Y, Feng Y, Liu Q, et al. Human endogenous retroviruses as epigenetic therapeutic targets in TP53-mutated diffuse large B-cell lymphoma. Signal Transduct Target Ther. 2023;8(1):381.
Li Y-R, Ochoa CJ, Zhu Y, Kramer A, Wilson M, Fang Y, Chen Y, Singh T, Di Bernardo G, Zhu E, et al. Profiling ovarian cancer tumor and microenvironment during disease progression for cell-based immunotherapy design. iScience. 2023;26(10):107952.